Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

DISCUS

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)

Currently recruiting

DREAMM-10

A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (NCT06679101)

The study will evaluate if belantamab mafodotin, lenalidomide and dexamethasone prolongs progression-free overall survival compared to daratumumab, lenalidomide and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Currently recruiting

DREAMM7

DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma – DREAMM 7 (NCT04246047)

Currently recruiting

Dren Bio DR-0201-AIM-001

A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)

The DR-0201-AIM-001 study is designed to evaluate the safety and efficacy of DR-0201 in adult participants with lupus, primary Sjögren’s syndrome and/or scleroderma.
Participants receive trial medication via an infusion over 26 weeks at varying intervals.
 

Currently recruiting

DRESS

Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)

No longer recruiting

DRI19220

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTEN] (NCT07170917)

The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe Hidradenitis Suppurativa (HS). Participants will be in the study for up to 60 weeks and have the option to enter a long-term extension study for an additional 52 weeks. The treatment will be administered via subcutaneous injection (small injection into the abdomen) every two weeks.
Currently recruiting

DUET-UC

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (NCT05242484)

Currently recruiting

DURGA-4 D8311C00001

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell [CAR-T] Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (NCT07391657)

A Phase III, Open-label, Randomised, Multicentre Study Comparing AZD0120 (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma.

Coming soon

DZ2022B0002

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT05824585)

Currently recruiting

E-nside INNER-B-APAC

INNER-B-APAC – Asian Pacific post-market clinical follow-up study in patients with thoracoabdominal aortic aneurysms treated with E-nside TAAA Multibranch Stent Graft System (NCT05954793)

Currently recruiting

E-TAN

A double-blinded randomised placebo-controlled trial of estradiol: investigating the effect on disordered eating symptoms of women with anorexia nervosa (ACTRN12623000897662)

Currently recruiting

ECMO-REHAB

A Randomised Controlled Trial of Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation (ECMO-Rehab) (NCT05003609)

No longer recruiting

EFC15951

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (NCT05405166)

Currently recruiting

EFC17600

A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (NCT06407934)

No longer recruiting

eFemoral

A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal Artery (NCT04584632)

This trial is looking at a new treatment called the Efemoral Vascular Scaffold System (EVSS), a tiny dissolvable scaffold coated with medication that helps keep blood flowing in narrowed or blocked leg arteries. VSS is designed to support the artery while it heals and then gradually dissolve, leaving the vessel free to move naturally. This may improve circulation, reduce symptoms like leg pain when walking, and support long-term artery health.
Currently recruiting

EFFECT

Investigating the immunomodulatory and clinical effects of fermentable fibre intervention to reduce symptoms of Long COVID (ACTRN12624000356561)

Currently recruiting

ELEVATE-HFpEF

Randomized trial of ELEVATEd cardiac pacing rate for personalized treatment of Heart Failure with preserved Ejection Fraction [ELEVATE-HFpEF] (NCT06678841)

Currently recruiting

ELOWEN-1

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (NCT07332481)

This trial aims to evaluate the safety and efficacy of enpatoran over 24 weeks in people with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration up to 35 weeks, Treatment Duration 24 weeks, Visit Frequency every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Coming soon

EMERALD-2

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who are at high risk of reccurence after curative hepatic resection or ablation (NCT03847428)

Currently recruiting

EMITT-1 GREY WOLF

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies (ACTRN12623000108617)

Currently recruiting
10 11 12 13 14